Early-stage ovarian cancer: Clinical outcome and analysis of prognostic factors—Results from a prospective registry of GEICO (Spanish Group for Ovarian Cancer Research).

ObjectiveThe objective of this study was to assess the clinical outcome of patients with recurrent early-stage ovarian cancer.MethodsThe hospital records of 87 patients were reviewed. The median follow-up of survivors from recurrence was 87.6 months.ResultsThe 25%, 50%, and 75% quantiles of time to recurrence were 15, 25, and 44 months, respectively. The pelvis was the most common site of failure (39.1%), followed by abdomen (18.3%) and retroperitoneal nodes (18.3%). Treatment at recurrence consisted of chemotherapy in 46 patients, surgery plus chemotherapy in 29, surgery in 3, surgery plus radiotherapy in 2, and other therapies in 7. A macroscopically complete cytoreduction was obtained in 29 (85.2%) of the 34 patients who underwent secondary surgery. Five- and 7-year survival rates after recurrence were 34.3% and 29.6%. By log-rank test, survival after recurrence was related to patient age (≤60 vs >60 years; P = 0.001), time to recurrence (>15 vs ≤15 months; P = 0.049), site of recurrence (retroperitoneum vs pelvis vs other; P = 0.004), and surgery at recurrence (yes vs not; P = 0.001), but not to substage, histotype, grade, prior adjuvant chemotherapy, examination that detected recurrence, and chemotherapy at recurrence. On multivariate analysis, patient age (hazard ratio, 1.836; 95% confidence interval, 1.060-3.180) and surgical treatment at recurrence (hazard ratio, 1.972; 95% confidence interval, 1.084–3.587) were independent prognostic variables for survival after recurrence.ConclusionsPatient age and surgery at recurrence were independent prognostic variables for patients with recurrent early-stage ovarian cancer. When feasible, salvage surgery appears to give a survival advantage in this clinical setting.

Download Full-text

Analysis of Clinicopathologic Factors and KRAS Gene Mutation in Epithelial Ovarian Cancer Outcomes

Open Access Macedonian Journal of Medical Sciences ◽

10.3889/oamjms.2020.5147 ◽

2020 ◽

Vol 8 (B) ◽

pp. 878-881

Author(s):

Andi Friadi ◽

Wirsma Arif Harahap ◽

Arni Amir ◽

Andri Andrijono

Keyword(s):

Ovarian Cancer ◽

Prognostic Factors ◽

Epithelial Ovarian Cancer ◽

Kras Mutation ◽

Early Stage ◽

Advanced Stage ◽

Kras Gene ◽

Clinicopathologic Factors ◽

Mutation Group ◽

Early Stage Ovarian Cancer

BACKGROUND: Raise of ovarian cancer mortality is caused by high ovarian cancer recurrence. This is related to many prognostic factors. Kirsten-rat sarcoma virus oncogene (KRAS) is a proto-oncogene that regulates proliferation, growth and cell motility. The controversy of some experts regarding KRAS mutations in the prognosis of ovarian cancer makes it interesting to analyze. AIM: The aim of this study is to clarify whether the clinicopathologic factors and KRAS gene mutation affect the recurrence of patients with ovarian cancer in Indonesia. METHODS: The authors conducted a retrospective cohort study. Clinicopathological factors and prognoses were obtained for 205 patients who were histopathologically diagnosed with epithelial ovarian cancer or ovarian borderline malignant tumor, operated from June 2015 to January 2019 at Dr. M. Djamil General Hospital. We gathered 80 patients who were diagnosed with epithelial ovarian cancer since June 2015 until January 2019. These cases were analyzed after 2-year follow-up or recurrence occurred. Survival rate was determined using the Kaplan–Meier method and examined by Log rank test. All analyses were performed using STATA ver. 12.0, with p < 0.05 considered to be significant. RESULTS: Among KRAS mutation group, the 2-year disease free survival rate (2y-DFS) was 31.56% and 47.58% in non-mutation group with significant differences between mutation and non-mutation (p = 0.02). There was a significant difference between early stage ovarian cancer with non-mutation group and advanced stages ovarian cancer with mutation group (p = 0.00). Among combination staging with mutation group, the 2y-DFS was 85.79% in early stage ovarian cancer with non-mutation, 44.44% in early stage with mutation, 10.65% in advanced stage with non-mutation, and 20.00% in advanced stage with mutation. CONCLUSION: The results suggest that staging and KRAS mutation are the most influence prognostic factors for epithelial ovarian cancer. There was a discrepancy of prognosis by staging and mutation between early stage with non-mutation and advanced stage with KRAS mutation.

Download Full-text

Three Biomarkers Identified From Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer

Yearbook of Pathology and Laboratory Medicine ◽

10.1016/s1077-9108(08)70087-2 ◽

2006 ◽

Vol 2006 ◽

pp. 117-118

Author(s):

A.V. Parwani

Keyword(s):

Ovarian Cancer ◽

Proteomic Analysis ◽

Early Stage ◽

Early Stage Ovarian Cancer

Download Full-text

UTERINE LAVAGE: AN OFFICE PROCEDURE WITH A PROMISING POTENTIAL FOR DIAGNOSING EARLY-STAGE OVARIAN CANCER THROUOGH LIQUID BIOPSY

10.26226/morressier.599bdc7ad462b80296ca189a ◽

2017 ◽

Author(s):

Tamar Perri

Keyword(s):

Ovarian Cancer ◽

Liquid Biopsy ◽

Early Stage ◽

Office Procedure ◽

Uterine Lavage ◽

Early Stage Ovarian Cancer

Download Full-text

ASSESSING THE RISK OF PELVIC AND PARA-AORTIC NODAL INVOLVEMENT IN APPARENT EARLY-STAGE OVARIAN CANCER: A PREDICTORS- AND NOMOGRAM-BASED ANALYSES

10.26226/morressier.597eedbad462b80296ca1636 ◽

2017 ◽

Author(s):

Hee Jin Kang

Keyword(s):

Ovarian Cancer ◽

Early Stage ◽

Nodal Involvement ◽

Early Stage Ovarian Cancer

Download Full-text

Comparison of the survival outcomes of laparoscopy versus laparotomy in treatment of early-stage ovarian cancer: a systematic review and meta-analysis

Journal of Ovarian Research ◽

10.1186/s13048-021-00793-1 ◽

2021 ◽

Vol 14 (1) ◽

Author(s):

Qingduo Kong ◽

Hongyi Wei ◽

Jing Zhang ◽

Yilin Li ◽

Yongjun Wang

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Early Stage ◽

Meta Analysis ◽

Progression Free Survival ◽

Cochrane Library ◽

Survival Outcomes ◽

Free Survival ◽

Review Manager ◽

Early Stage Ovarian Cancer

Abstract Background Laparoscopy has been widely used for patients with early-stage epithelial ovarian cancer (eEOC). However, there is limited evidence regarding whether survival outcomes of laparoscopy are equivalent to those of laparotomy among patients with eEOC. The result of survival outcomes of laparoscopy is still controversial. The aim of this meta-analysis is to analyze the survival outcomes of laparoscopy versus laparotomy in the treatment of eEOC. Methods According to the keywords, Pubmed, Embase, Cochrane Library and Clinicaltrials.gov were searched for studies from January 1994 to January 2021. Studies comparing the efficacy and safety of laparoscopy versus laparotomy for patients with eEOC were assessed for eligibility. Only studies including outcomes of overall survival (OS) were enrolled. The meta-analysis was performed using Stata software (Version 12.0) and Review Manager (Version 5.2). Results A total of 6 retrospective non-random studies were included in this meta-analysis. The pooled results indicated that there was no difference between two approaches for patients with eEOC in OS (HR = 0.6, P = 0.446), progression-free survival (PFS) (HR = 0.6, P = 0.137) and upstaging rate (OR = 1.18, P = 0.54). But the recurrence rate of laparoscopic surgery was lower than that of laparotomic surgery (OR = 0.48, P = 0.008). Conclusions Laparoscopy and laparotomy appear to provide comparable overall survival and progression-free survival outcomes for patients with eEOC. Further high-quality studies are needed to enhance this statement.

Download Full-text